移动健康监测新发房颤复发的依从性研究
本研究基于RACE 7 ACWAS随机试验,评估437例新发症状性房颤患者急诊就诊后接受4周移动健康处方(每日三次及有症状时用ECG手持设备记录1分钟)的依从性。335例使用设备患者中位总体依从性83.3%,中位监测天数27/27天,85.7%患者至少每日一次测量持续使用;较高年龄和既往房颤阵发与依从性相关。
要点
- 4周移动健康监测新发房颤复发可行,85.7%患者至少每日一次持续使用设备。
- 中位总体依从性83.3%,中位完整监测天数为16/27天。
- 较高年龄和既往房颤阵发是依从性较高的多变量校正相关因素。
核心结论
- 在新发症状性房颤患者急诊就诊后,4周移动健康监测处方可行,85.7%患者至少每日一次持续使用设备。
- 较高年龄患者依从性更高。
研究设计与样本
- 本研究为RACE 7 ACWAS随机试验的子分析,纳入437例急诊就诊的新发症状性房颤患者,无论随机分组(早期或延迟复律)。
- 要求患者使用ECG手持设备每日三次及有症状时记录1分钟心率和节律,持续4周(如可用)。
- 依从性以完成测量次数占要求记录次数的比例评估,并评估纵向依从一致性;所有使用手持设备的患者纳入本亚组分析。
主要发现
- 335例患者纳入分析(58%男性;中位年龄67岁,IQR 11)。
- 所有患者中位总体依从性为83.3%(IQR 29.9%)。
- 中位监测天数为27/27天(IQR 5),中位完整监测天数为16/27天(IQR 14)。
- 较高年龄和既往房颤阵发被确定为与依从性相关的多变量校正因素。
临床怎么用
- 对于急诊就诊的新发症状性房颤患者,可考虑处方4周移动健康ECG手持设备监测房颤复发,依从性总体较高。
- 较高年龄和既往房颤阵发患者可能依从性更好,可优先考虑此类监测策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Rate Control versus Electrical Cardioversion Trial 7-Acute Cardioversion versus Wait and See trial compared early to delayed cardioversion for patients with recent-onset symptomatic atrial fibrillation (AF). This study aims to evaluate the adherence to a 4-week mobile health (mHealth) prescription to detect AF recurrences after an emergency department visit. METHODS: After the emergency department visit, the 437 included patients, irrespective of randomisation arm (early or delayed cardioversion), were asked to record heart rate and rhythm for 1 min three times daily and in case of symptoms by an electrocardiography-based handheld device for 4 weeks (if available). Adherence was appraised as number of performed measurements per number of recordings asked from the patient and was evaluated for longitudinal adherence consistency. All patients who used the handheld device were included in this subanalysis. RESULTS: 335 patients (58% males; median age 67 (IQR 11) years) were included. The median overall adherence of all patients was 83.3% (IQR 29.9%). The median number of monitoring days was 27 out of 27 (IQR 5), whereas the median number of full monitoring days was 16 out of 27 (IQR 14). Higher age and a previous paroxysm of AF were identified as multivariable adjusted factors associated with adherence. CONCLUSIONS: In this randomised trial, a 4-week mHealth prescription to monitor for AF recurrences after an emergency department visit for recent-onset AF was feasible with 85.7% of patients consistently using the device with at least one measurement per day. Older patients were more adherent. TRIAL REGISTRATION NUMBER: NCT02248753.
引用
- van der Velden RMJ, Pluymaekers NAHA, Dudink EAMP, et al. Mobile health adherence for the detection of recurrent recent-onset atrial fibrillation. Heart. 2022. PMID: 36322782. doi:10.1136/heartjnl-2022-321346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。